<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05050760</url>
  </required_header>
  <id_info>
    <org_study_id>KY20212101-C-1</org_study_id>
    <nct_id>NCT05050760</nct_id>
  </id_info>
  <brief_title>DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer</brief_title>
  <official_title>An Exploratory Study of the Efficacy and Safety of DCF Regimen Combined With Camrelizumab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma(ESCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of&#xD;
      locally advanced ESCC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome:&#xD;
&#xD;
      To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of&#xD;
      locally advanced ESCC&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      pathologic complete response (pCR)、Major Pathologic Response（MPR）、R0 resection rate、Objective&#xD;
      response rate（ORR）、Disease free survival（DFS）、Relief rate and safety of dysphagia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients fulfilling Eligibility Criteria will be included in our study.After three cycles of resectable esophageal cancer treated with DCF combined with camrelizumab neoadjuvant therapy, the researchers determined whether the patient should undergo surgical treatment according to clinical diagnosis and patient willingness.If the patient underwent surgery, surgery was performed 6-8 weeks after discontinuation;If the patient did not receive surgical treatment, the patient was continued to receive 3 cycles of adjuvant therapy with camrelizumab combined with DCF regimen</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Feasibility（Incidence of Treatment-Emergent Adverse Events）</measure>
    <time_frame>12months</time_frame>
    <description>All participants with treatment-related adverse events as assessed by National Cancer Institute Common Terminology Criteria for Adverse Event,Version 5.0(CTC AE5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic Complete Response (PCR)</measure>
    <time_frame>1 month after resection</time_frame>
    <description>PCR is defined as pT0N0M0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major pathologic response (MPR)</measure>
    <time_frame>1 month after resection</time_frame>
    <description>MPR is defined as viable tumor comprised ≤ 10% of resected tumor specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>3 and 5 years</time_frame>
    <description>Percentage of Participants With DFS, as Assessed by RECIST 1.1. DFS is defined as the time from randomization to the first documented disease progression of local recurrence or distant metastasis or death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>ESCC</condition>
  <arm_group>
    <arm_group_label>The experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug：DCF+Camrelizumab Camrelizumab:200mg/time,IV,Q3W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.</description>
    <arm_group_label>The experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCF</intervention_name>
    <description>DCF:Oxaliplatin (85mg/ m^2, IV D1,Q3W.Docetaxel: 60 mg/m^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA&lt;1.25^2,40 mg/time,1.25^2&lt;BSA&lt;1.5^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks</description>
    <arm_group_label>The experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-75 years old patients with esophageal cancer, male and female.&#xD;
&#xD;
          2. A patient with esophageal squamous cell carcinoma diagnosed by pathology.&#xD;
&#xD;
          3. Initial treatment, no previous surgery.&#xD;
&#xD;
          4. Subjects were patients with resectable locally advanced ESCC(AJCC V8 TNM&#xD;
             classification),tumor node metastasis classification(TNM)&#xD;
&#xD;
          5. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group(ECOG)&#xD;
             Performance Scale.&#xD;
&#xD;
          6. Expected survival ≥ 3 months.&#xD;
&#xD;
          7. All patients should have measurable or evaluable target lesions.&#xD;
&#xD;
          8. Able to eat more than a liquid diet; No preesophageal perforation signs; There was no&#xD;
             distant metastasis and the operation was tolerated.&#xD;
&#xD;
          9. Demonstrate adequate organ function.&#xD;
&#xD;
         10. Male subjects whose partners are women of childbearing age should be surgically&#xD;
             sterilized or agree to use an effective method of contraception during the study&#xD;
             period and for 3 months after the last study administration.&#xD;
&#xD;
         11. The subjects voluntarily joined the study and signed the informed consent, with good&#xD;
             compliance and follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who did not meet the inclusion criteria for pathological type and primary&#xD;
             site.&#xD;
&#xD;
          2. Known to be allergic to macromolecular protein preparations, or components of&#xD;
             carilizumab, or to loplatin, docetaxa, sergiol, contrast agents and their&#xD;
             preparations.&#xD;
&#xD;
          3. Risk of esophageal perforation or presence of esophageal ulcers.&#xD;
&#xD;
          4. There is evidence of distant organ metastasis.&#xD;
&#xD;
          5. Surgical treatment (except biopsy), radiotherapy, chemotherapy, and molecular targeted&#xD;
             therapy have been performed.&#xD;
&#xD;
          6. had other malignant tumors ever.&#xD;
&#xD;
          7. History of severe lung or heart disease.&#xD;
&#xD;
          8. Active infection or fever of unknown cause &gt; 38.5℃ in the 2 weeks prior to&#xD;
             randomization (fever due to tumor can be included in the study as determined by the&#xD;
             investigator).&#xD;
&#xD;
          9. Significant active infection is known, or the investigator determines the presence of&#xD;
             significant blood, renal, metabolic, gastrointestinal, or endocrine dysfunction.&#xD;
&#xD;
         10. Have a history of immunodeficiency, including HIV positive or other acquired or&#xD;
             congenital immunodeficiency diseases, or a history of organ transplantation.&#xD;
&#xD;
         11. Subjects requiring systematic treatment with corticosteroids (&gt;10mg/ day of prednisone&#xD;
             efficacy dose) or other immunosuppressive agents within 14 days prior to the first&#xD;
             study drug. In the absence of active autoimmune disease, inhaled or topical steroid&#xD;
             use and adrenal corticosteroid replacement at a dose &gt;10mg/ day of prednisone efficacy&#xD;
             dose were permitted.&#xD;
&#xD;
         12. Participants had active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), and&#xD;
             hepatitis C (HCV antibody positive and HCV-RNA higher than the lower limit of the&#xD;
             assay).&#xD;
&#xD;
         13. Those who had received live vaccine within 3 months prior to treatment.&#xD;
&#xD;
         14. In the midst of acute or chronic tuberculosis infection.&#xD;
&#xD;
         15. Patients were enrolled in clinical trials of other antitumor drugs within 4 weeks.&#xD;
&#xD;
         16. IV fluids cannot be administered.&#xD;
&#xD;
         17. She has a history of gastrointestinal ulcer, gastrointestinal bleeding and&#xD;
             perforation.&#xD;
&#xD;
         18. Have a history of gastrointestinal ulcer, gastrointestinal bleeding and perforation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianjun Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianjun Yang, Dr.</last_name>
    <phone>0086-13572533693</phone>
    <email>Jianjunyang66@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guanghui Xu, Dr.</last_name>
    <phone>0086-17791826711</phone>
    <email>xuguanghui8@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianjun Yang, Dr.</last_name>
      <phone>0086-13572533693</phone>
      <email>Jianjunyang66@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Guanghui Xu, Dr.</last_name>
      <phone>0086-17791826711</phone>
      <email>xuguanghui8@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

